The ErbB2 inhibitor Herceptin (Trastuzumab) promotes axonal outgrowth four weeks after acute nerve transection and repair.
RatOtherSprague-DawleyFemaleAdministered after nerve transection and surgical repair; outcomes assessed at…
Model: Common peroneal nerve transection with immediate surgical repair
Trastuzumab had no impact on the numbers of motor or sensory neurons regenerating their axons and did not alter ErbB2 or phospho-ErbB2 expression levels, but significantly increased the number of regenerated axons in the distal repaired nerve at 4 weeks, indicating more axons emitted per regenerati…
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.